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Pharmacological inhibition of the oncogenic PI3Kδ path-
way has been shown to be efficacious in patients with
hematopoietic malignancies. However, its therapeutic
application in patients with solid tumors has not yet been
tested. Recently, genetic inactivation of PI3Kδ in mice
was shown to delay the growth of solid tumors, resulting
from the inactivation of Treg-mediated suppression of
cytotoxic CD8+ T cell responses. Therefore we explored
the immunotherapeutic potential of our PI3Kδ-selective
compound, INCB050465, in multiple preclinical tumor
models. We demonstrate that INCB050465 can block
tumor growth in multiple established tumor models
which are not dependent upon oncogenic PI3K signaling.
Tumor growth inhibition is not observed in these models
in immunocompromised mice, demonstrating that the
anti-tumor effects of these agents require an intact
immune system. To further investigate the immune-
mediated mechanisms, tumors exposed to vehicle or
INCB050465 were harvested and analyzed for modula-
tion of gene expression and immune phenotype.
INCB050465 was shown to significantly downregulate
T cell gene signatures in tumors, and this was primarily
due to depletion of CD4+CD25+FoxP3+ regulatory
T cells. In contrast, the number of CD8+ T cells was
shown to be higher in INCB050465-treated tumors. We
next examined INCB050465 in combination with other
immune modulators. The combination of PI3Kδ and JAK
inhibition resulted in enhanced activity in a T cell-
inflamed model by reducing both Treg and M2 macro-
phages, which then allowed the re-activation of both
CD4 and CD8 T cells. In addition, PI3Kδ inhibition and
PD-L1 blockade resulted in enhanced efficacy by deplet-
ing Treg and prolonging T cell responses over time. In
summary, inactivation of PI3Kδ with a pharmacological
inhibitor can enhance anti-tumor immunity by depleting
Treg while increasing the numbers of cytotoxic CD8+
T cells. These data support clinical evaluation of the
mechanism, and further studies to understand the mole-
cular basis of efficacy and associated cellular responses
may provide a rationale to identify individuals who may
benefit most from PI3Kδ inhibitor-based immunotherapy
combinations in the clinic.
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